

# Στυλιανός Παναγούτσος Καθηγητής Νεφρολογίας ΔΠΘ

## ΣΥΝΟΠΤΙΚΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

### *Προσωπικά στοιχεία*



Όνομα:	Στυλιανός
Επώνυμο:	Παναγούτσος
Πατρώνυμο:	Αθανάσιος
Ημερομηνία γέννησης:	14 Δεκεμβρίου 1960
Τόπος Γέννησης:	Νέα Ιωνία Αττικής
Διεύθυνση Κατοικίας:	Οδυσσέως 9, Αλεξανδρούπολη
Ηλεκτρονική διεύθυνση:	<a href="mailto:spanagou@med.duth.gr">spanagou@med.duth.gr</a>
Τηλέφωνα:	2551353144, 2551353145
Οικογενειακή κατάσταση:	Παντρεμένος με τη Μαρία Σαμακουρή, 1 κόρη
Ξένες γλώσσες:	Αγγλικά, Γαλλικά

## ***Τίτλοι Σπουδών***

- 1978: Απολυτήριο Βαρβακείου Προτύπου Σχολής  
Βαθμός: Λίαν Καλώς
- 1985: Πτυχίο Ιατρικής Σχολής Πανεπιστημίου Αθηνών  
Βαθμός: Λίαν Καλώς
- 1994: Ειδικότητα Νεφρολογίας
- 1996: Διδακτορική διατριβή  
Ιατρική Σχολή Δημοκρίτειου Πανεπιστημίου Θράκης  
Βαθμός: Άριστα

## ***Υποτροφίες***

- 1978 – 1985: Υπότροφος «Λάτσειου Ιδρύματος»

## ***Μεταδιδακτορική εκπαίδευση***

- Μάιος – Σεπτέμβριος 2012 Μετεκπαίδευση σε θέματα που αφορούν ασθενείς με Σπειραματοπάθειες και ασθενείς υποψήφιους για μεταμόσχευση και με νεφρικό μόσχευμα στο Renal Section, Department of Medicine Imperial College and Renal Medicine and Transplantation, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London

## ***Επαγγελματική απασχόληση***

1985 – 1987:	Στρατιωτική θητεία ως δόκιμος έφεδρος ανθυπίατρος
1987:	Ειδικευόμενος στην Παθολογία 401 Γενικό Στρατιωτικό Νοσοκομείο Αθηνών
1988 – 1989:	Αγροτικός Ιατρός Λυκόφως, νομού Έβρου
1989 – 1990:	Ειδικευόμενος Παθολογίας Πανεπιστημιακή Παθολογική Κλινική Γενικό Περιφερειακό Νοσοκομείο Αλεξανδρούπολης
1990 – 1994:	Ειδικευόμενος Νεφρολογίας Πανεπιστημιακή Νεφρολογική Κλινική Γενικό Περιφερειακό Νοσοκομείο Αλεξανδρούπολης
1995 – 1998:	Επιμελητής Β΄ ΕΣΥ Πανεπιστημιακή Νεφρολογική Κλινική Γενικό Περιφερειακό Νοσοκομείο Αλεξανδρούπολης
1998 – 2003	Λέκτορας Νεφρολογίας Δ. Π. Θράκης Πανεπιστημιακή Νεφρολογική Κλινική Γενικό Περιφερειακό Νοσοκομείο Αλεξανδρούπολης
2003 – 2011	Επίκουρος Καθηγητής Νεφρολογίας Δ.Π.Θράκης Πανεπιστημιακή Νεφρολογική Κλινική Πανεπιστημιακό Γενικό Νοσοκομείο Αλεξανδρούπολης
2011 – 2017	Αναπληρωτής Καθηγητής Νεφρολογίας Δ. Π. Θράκης Πανεπιστημιακή Νεφρολογική Κλινική Πανεπιστημιακό Γενικό Νοσοκομείο Αλεξανδρούπολης
Μάιος – Σεπτέμβριος 2012	Honorary Clinical Fellow, Renal Medicine and Transplantation, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London and Visiting Researcher, Renal Section, Department of Medicine Imperial College, London
2017 – σήμερα	Καθηγητής Νεφρολογίας Δ. Π. Θράκης Πανεπιστημιακή Νεφρολογική Κλινική Πανεπιστημιακό Γενικό Νοσοκομείο Αλεξανδρούπολης

## ***Βραβεία***

***2022: Εύφημος μνεία της επιτροπής βραβείου εξαίρετης διδασκαλίας του Δημοκρίτειου Πανεπιστημίου Θράκης***

### ***Ερευνητικά ενδιαφέροντα***

Αναιμία της Χρόνιας Νεφρικής Νόσου

Επάρκεια Κάθαρσης

Αγγειακή προσπέλαση αιμοκαθαρόμενων ασθενών

### ***Κλινικό έργο***

Διευθυντής Πανεπιστημιακής Νεφρολογικής Κλινικής Πανεπιστημιακού Γενικού Νοσοκομείου Αλεξανδρούπολης.

Τμήματα Πανεπιστημιακής Κλινικής:

1. Νοσηλευτική μονάδα
2. Μονάδα Τεχνητού Νεφρού και Πλασμαφαίρεσης
3. Μονάδα Περιτοναϊκής Κάθαρσης
4. Εργαστήριο Παθοφυσιολογίας- Νεφρού- Μεταβολικών Νοσημάτων
5. Εξωτερικά Ιατρεία: Χρόνιας Νεφρικής Νόσου, Διαβητικής Νεφροπάθειας, Υπέρτασης, Σπειραματοπαθειών, Μεταμόσχευσης νεφρού, Προμεταμοσχευτικού ελέγχου

### ***Διδακτικό έργο***

#### *Προπτυχιακό*

Υποχρεωτικό μάθημα 10<sup>ου</sup> εξαμήνου «Νεφρολογία» (Συντονιστής)

Υποχρεωτικό μάθημα 5<sup>ου</sup> εξαμήνου «Παθοφυσιολογία»

Επιλεγόμενο μάθημα «Υγρά Ηλεκτρολύτες και οξεοβασική ισορροπία»

#### *Μεταπτυχιακό*

ΜΠΣ «Μεθοδολογία της σύγχρονης αντιμετώπισης της Νεφρικής Ανεπαρκείας»  
(Διευθυντής)

ΜΠΣ «Αγγειακά Εγκεφαλικά Επεισόδια»

ΜΠΣ «Κλινική Φαρμακολογία»

## ***Συμμετοχή σε επιτροπή σύνταξης περιοδικού***

Μέλος της επιτροπής σύνταξης του περιοδικού ***ΕΛΛΗΝΙΚΗ ΝΕΦΡΟΛΟΓΙΑ***  
από τον Ιανουάριο του 2005

## ***Κριτής εργασιών σε διεθνή και ελληνικά επιστημονικά περιοδικά και σε συνέδρια***

Έχω υπάρξει κριτής εργασιών στα περιοδικά και στα συνέδρια:

***ΕΛΛΗΝΙΚΗ ΝΕΦΡΟΛΟΓΙΑ***

***PERITONEAL DIALYSIS***

***INTERNATIONAL UROLOGY AND NEPHROLOGY***

***CLINICAL NEPHROLOGY***

***RENAL FAILURE***

## ***Συμμετοχή σε Επιστημονικές εταιρείες***

Αντιπρόεδρος του Δ.Σ. της Ελληνικής Νεφρολογικής Εταιρείας

Μέλος της Ευρωπαϊκής εταιρείας Νεφρολογίας ERA-EDTA

Μέλος της Παγκόσμιας εταιρείας Νεφρολογίας ISN

Πλήρες μέλος του General Medical Council, UK

## *Δημοσιεύσεις*

### *Publications in peer-reviewed international journals*

#### **1. Evaluation of CNS-Function in CAPD Patients Using Magnetoencephalography (MEG): Comparison with Hemodialysis Patients**

E. Thodis, P. A. Anninos, P. Pasadakis, A. V. Adamopoulos, S. Panagoutsos, V. Vargemezis.

*ADVANCES IN PERITONEAL DIALYSIS/1992, Vol 8, pp:181-184.*

#### **2. Treatment of CAPD Peritonitis with Clavulanate Potentiated Ticarcillin**

P. Pasadakis, E. Thodis, A. Euthimiadou, S. Panagoutsos, E. Oustoglou, S. Kartali, V. Vargemezis.

*ADVANCES IN PERITONEAL DIALYSIS/1992, Vol 8, pp:238-241.*

#### **3. Treatment and Prevention of Relapses of CAPD Pseudomonas Peritonitis**

P. Pasadakis, E. Thodis, A. Eftimiadou, S. Panagoutsos, D. Papazoglou, M. Kaliengidou, S. Kartali, V. Vargemezis.

*ADVANCES IN PERITONEAL DIALYSIS/1993, Vol 9, pp:206-210.*

#### **4. The Identification of Bone Mineral Density (BMD) in CAPD in comparison with HD Patients.**

P. Pasadakis, E. Thodis, G. Manavis, E. Mourvati, S. Panagoutsos, V. Vargemezis.

*ADVANCES IN PERITONEAL DIALYSIS/1995, Vol 11:247*

#### **5. Evaluation of changes in serum and dialysate levels of cancer antigen (CA 125) in stable CAPD patients**

Ploumis Passadakis, Stelios Panagoutsos, Elias Thodis, Irimi Tsivara, Fotini Sopassi, Vassilis Vargemezis

*ADVANCES IN PERITONEAL DIALYSIS 1999; 15:40-44.*

#### **6. Failure of Icodextrin to provide adequate ultrafiltration in continuous ambulatory peritoneal dialysis patients**

Elias Thodis, Ploumis Passadakis, Stelios Panagoutsos, Dimitrios Marinopoulos, Vassilis Vargemezis

*ADVANCES IN PERITONEAL DIALYSIS 1999; 15: 171-174.*

**7. Outcome for continuous ambulatory peritoneal dialysis patients is not predicted by peritoneal permeability characteristics**

Passadakis PS, Thodis ED, Panagoutsos SA, Selisiou CA, Pitta EM, Vargemezis VA.

*ADVANCES IN PERITONEAL DIALYSIS 2000;16:2-6.*

**8. The Effectiveness of Mupirocin preventing S. Aureus in PD catheter related infections**

E. Thodis, P. Passadakis, S. Panagoutsos, D. Bacharaki, A. Euthimiadou, V. Vargemezis

*ADVANCES IN PERITONEAL DIALYSIS 2000; 16:257-61.*

**9. The Progression of Uremic Polyneuropathy in Patients on Hemodialysis and Hemofiltration**

Mourvati EP, Passadakis PS, Thodis ED, Panagoutsos SA, Galtsidopoulos OG, Vargemezis VA

*Hemodial Int. 2001 Jan;5(1):37-41 IMPACTFACTOR: 1.543*

**10. The Clinical Impact of Increasing the Hemodialysis Dose**

Panagoutsos SA, Yannatos EV, Passadakis PS, Thodis ED, Galtsidopoulos OG, Vargemezis VA

*Hemodial Int. 2001 Jan;5(1):51-54 IMPACTFACTOR: 1.543*

**11. Effects of hemodialysis dose on anemia, hypertension, and nutrition**

Stelios A. Panagoutsos, Evangelos V. Yannatos, Ploumis S. Passadakis, Elias D. Thodis, Omiros G. Galtsidopoulos, and Vassilis A. Vargemezis

*RENAL FAILURE 24 (5): 615-621, 2002 IMPACTFACTOR: 0.840*

**12. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients**

Christina I. Fytili, Euaggelia G. Progia, Stelios A. Panagoutsos, Elias D. Thodis, Ploumis S. Passadakis, Kostas I. Sombolos, Vassilis A. Vargemezis  
*RENAL FAILURE 24 (5): 623-630, 2002 IMPACTFACTOR: 0.840*

**13. Hypotension in patients on Chronic Peritoneal Dialysis: Etiology, Management, and outcome**

M. Malliara, P. Passadakis, S. Panagoutsos, M. Theodoridis, E. Thodis, J. Bargman, V. Jassal, S. Vas, V. Vargemezis, D. Oreopoulos  
*ADVANCES IN PERITONEAL DIALYSIS 2002; 18:49-54*

**14. Peritoneal catheter exit-site infections: predisposing factors, prevention and treatment.**

Thodis E, Passadakis P, Ossareh S, Panagoutsos S, Vargemezis V, Oreopoulos DG  
*INT J ARTIF ORGANS. 2003 Aug;26(8):698-714 IMPACTFACTOR: 1.417*

**15. Use of short PTFE segments (<6 cm) compares favorably with pure autologous repair in failing or thrombosed native arteriovenous fistulas**

Georgiadis GS, Lazarides MK, Lambidis CD, Panagoutsos SA, Kostakis AG, Bastounis EA, Vargemezis VA.  
*J VASC SURG. 2005 Jan;41(1):76-81 IMPACTFACTOR: 3.517*

**16. Peritoneal catheters and related infections**

Thodis E, Passadakis P, Lyrantzopoulos N, Panagoutsos S, Vargemezis V, Oreopoulos D.  
*INT UROL NEPHROL 2005;37(2):379-393 IMPACTFACTOR: 1.053*

**17. Efficient monthly subcutaneous administration of darbepoetin in stable CAPDpatients.**

Theodoridis M, Passadakis P, Kriki P, Panagoutsos S, Yannatos E, Kantartzi K, Sivridis D, Vargemezis V.  
*PERITONEAL DIALYSIS INTERNATIONAL 2005 Nov-Dec;25(6):564-569 IMPACT FACTOR: 1.636*



**18. Timely transfer of peritoneal dialysis patients to hemodialysis improves survival rates**

Panagoutsos S, Kantartzi K, Passadakis P, Yannatos E, Mourvati E, Theodoridis M, Kriki P, Thodis E, Vargemezis V

*CLINICAL NEPHROLOGY 2006 Jan;65(1):43-47 IMPACT FACTOR: 1.373*

**19. Tuberculous spondylitis in patients with end-stage renal disease undergoing chronic hemodialysis therapy**

Verettas DJ, Ververidis AN, Boyiatzis C, Panagoutsos S, Galanis V, Passadakis P, Kazakos K, Vargemezis V

*CLINICAL NEPHROLOGY 2006 Apr;65(4):299-302 IMPACT FACTOR: 1.373*

**20. Urological management of indinavir-associated acute renal failure I HIV-positive patients**

C. Kalaitzis, P. Passadakis, S. Giannakopoulos, S. Panagoutsos, E. Mpantis, A. Triantafyllidis, S. Touloupidis, V. Vargemezis

*INTERNATIONAL UROLOGY AND NEPHROLOGY 2007, 39: 743-746 IMPACT FACTOR: 1.053*

**21. Homecare telematics for peritoneal dialysis**

Kaldoudi, E., Passadakis, P., Panagoutsos, S., Vargemezis, V.

*JOURNAL ON INFORMATION TECHNOLOGY IN HEALTHCARE 2007, Vol 5, Issue 6, pp: 372-378*

**22. The Alteration of Dialysate Cancer Antigen 125 Concentration Under a Biocompatible Bicarbonate Peritoneal Dialysis Solution and the Preservation of the Mesothelial Cell Viability**

Theodoridis M., Passadakis P., Kriki P., Gioka T., Panagoutsos S., Mourvati E., Thodis E., Kantartzi K., Vargemezis V.

*RENAL FAILURE 30 (2): 161 - 167, 2008 IMPACT FACTOR: 0.840*

**23. Surgical revision of complicated false and true vascular access-related aneurysms**

George S. Georgiadis, Miltos K. Lazarides, Stelios A. Panagoutsos, Konstantia M. Kantartzi, Constantinos D. Lambidis, Dimitrios N. Stamos, Vassilios A. Vargemezis  
*JOURNAL VASCULAR SURGERY 2008;47:1284-91 IMPACTFACTOR: 3.517*

**24. Acute Exercise May Exacerbate Oxidative Stress Response in Hemodialysis Patients**

Ioannis G. Fatouros, Ploumis Pasadakis, Apostolos Sovatzidis, Athanasios Chatzinikolaou, Stylianos Panagoutsos, Dimitrios Sivridis, Ioannis Michailidis, Ioannis Douroudos, Kiriakos Taxildaris, Vasilios Vargemezis  
*NEPHRON CLIN PRACT 2008;109:c55-c64 IMPACTFACTOR: 1.606*

**25. Unexpectedly high incidence of brucellosis in one university dialysis unit of North East Greece.**

Kantartzi K, Panagoutsos S, Kokkinou V, Passadakis P, Vargemezis V.  
*NEPHROL DIAL TRANSPLANT 2009 Jun;24(6):2003-4. IMPACTFACTOR: 3.306*

**26. A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient**

Kriki P, Thodis E, Deftereos S, Panagoutsos S, Theodoridis M, Kantartzi K, Mourvati E, Prassopoulos P, Passadakis P, Vargemezis V  
*CLINICAL NEPHROLOGY 2009 Jun;71(6):714-8 IMPACT FACTOR: 1.373*

**27. Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma.**

Vargemezis V, Liakopoulos V, Kriki P, Panagoutsos S, Leontsini M, Passadakis P, Thodis E.  
*AMERICAN JOURNAL OF KIDNEY DISEASE 2010 Jan;55(1):144-7 IMPACT FACTOR: 5.152*

**28. Chromosome Instability in Patients with Chronic Renal Failure**

Theodoros Lialiaris, Polyxeni Mavromatidou, Evangelos Digkas, Theoktisti Passadaki, Panagiotis Mpountoukas, Stylianos Panagoutsos, and Vassilios Vargemezis  
*GENETIC TESTING AND MOLECULAR BIOMARKERS 2010 14(1):37-41 IMPACT FACTOR: 1.110*

**29. L-carnitine Effects on Oxidative Stress Responses in Patients With Renal Disease**

Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, Taxildaris K, Vargemezis V

*MEDICINE & SCIENCE IN SPORTS & EXERCISE. 2010 42(10):1809-1818  
IMPACT FACTOR: 3.707*

**30. Brucellosis in dialysis patients. Does it exist?**

Kantartzi K, Panagoutsos S, Kokkinou V, Alepopoulou E, Mourvati E, Passadakis P, Vargemezis V

*CLINICAL NEPHROLOGY 2010 Apr;73(4):309-13 IMPACT FACTOR: 1.373*

**31. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis.**

Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I, Panagoutsos S, Passadakis P, Vargemezis V, Magotti P, Qu H, Mollnes TE, Ritis K, Lambris JD.

*BLOOD 2010 JUL 29;116(4):631-9 IMPACTFACTOR: 10.555*

**32. A hybrid approach to salvage a failing long-standing autogenous aneurysmal fistula in a hemodialysis patient.**

Georgiadis GS, Nikolopoulos E, Papanas N, Mourvati E, Panagoutsos S, Lazarides MK.

*Int J Artif Organs. 2010 Nov; 33(11):819-23 IMPACTFACTOR: 1.05*

**33. Metformin-related lactic acidosis in patients with acute kidney injury**

Devetzis V, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E, Georgoulidou A, Vargemezis V.

*Int Urol Nephrol. 2011 Dec;43(4):1243-8 IMPACT FACTOR: 1.053*

**34. Can dialysis modality influence quality of life in chronic hemodialysis patients? Low-flux hemodialysis versus high-flux hemodiafiltration: a cross-over study**

Kantartzi K, Panagoutsos S, Mourvati E, Roumeliotis A, Leivaditis K, Devetzis V, Passadakis P, Vargemezis V

*Ren Fail.* 2013;35(2):216-21 IMPACT FACTOR: 0.941

**35. Vascular access for hemodialysis: postoperative evaluation and function monitoring**

Leivaditis K, Panagoutsos S, Roumeliotis A, Liakopoulos V, Vargemezis V.

*Int Urol Nephrol.* 2014 Feb;46(2):403-9 IMPACT FACTOR: 1.519

**36. Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients**

Georgiadis GS, Georgakarakos EI, Antoniou GA, Panagoutsos S, Argyriou C, Mourvati E, Passadakis P, Lazarides MK

*J Vasc Surg.* 2014 Aug;60(2):462-70 IMPACT FACTOR: 3.454

**37. Ambulatory aortic blood pressure, wave reflections and pulse wave velocity are elevated during the third in comparison to the second interdialytic day of the long interval in chronic haemodialysis patients**

Koutroumbas G, Georgianos PI, Sarafidis PA, Protogerou A, Karpetas A, Vakianis P, Raptis V, Liakopoulos V, Panagoutsos S, Syrganis C, Passadakis P

*Nephrol Dial Transplant.* 2015 Dec 30(12):2046-53 IMPACT FACTOR: 4.085

**38. Low T3 syndrome and long-term mortality in chronic hemodialysis patients**

Fragidis S, Sombolos K, Thodis E, Panagoutsos S, Mourvati E, Pikilidou M, Papagianni A, Pasadakis P, Vargemezis V

*World J Nephrol.* 2015 Jul 6;4(3):415-22

**39. Chronic renal failure, diabetes mellitus type-II, and gestation: an overwhelming combination**

Kontomanolis EN, Panagoutsos S, Pasadakis P, Koukouli Z, Liberis A

*Clin Exp Obstet Gynecol.* 2016;43(2):276-8 IMPACT FACTOR: 0.52

**40. Comparison of multiple fluid status assessment methods in patients on chronic hemodialysis**

Alexiadis G, Panagoutsos S, Roumeliotis S, Stibiris I, Markos A, Kantartzi K, Passadakis P.

*Int Urol Nephrol.* 2017 Mar;**49**(3):525-532 *IMPACT FACTOR:*1.692

**41. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy**

Roumeliotis S, Roumeliotis A, Panagoutsos S, Giannakopoulou E, Papanas N, Manolopoulos VG, Passadakis P, Tavidou A

*J Diabetes Complications.* 2017 Oct;**31**(10):1527-1532 *IMPACT FACTOR:* 2.792

**42. A Comparative Study of Short-Term Blood Pressure Variability in Hemodialysis Patients with and without Intradialytic Hypertension**

Bikos A, Angeloudi E, Memmos E, Loutradis C, Karpetas A, Ginikopoulou E, Panagoutsos S, Pasadakis P, Liakopoulos V, Papagianni A, Sarafidis P.

*Am J Nephrol.* 2018;**48**(4):295-305 *IMPACT FACTOR:* 2.961

**43. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy**

Roumeliotis AK, Roumeliotis SK, Panagoutsos SA, Tsetsos F, Georgitsi M, Manolopoulos V, Paschou P, Passadakis PS

*Int Urol Nephrol.* 2018 Feb;**50**(2):321-329 *IMPACT FACTOR:* 1.596

**44. IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology**

Stangou M, Papatiririou M, Xydakis D, Oikonomaki T, Marinaki S, Zerbala S, Stylianou C, Kalliakmani P, Andrikos A, Papadaki A, Balafa O, Golfopoulos S, Visvardis G, Moustakas G, Papachristou E, Kouloukourgiotou T, Kapsia E, Panagiotou A, Koulousios C, Kavlakoudis C, Georgopoulou M, Panagoutsos S, Vlahakos DV, Apostolou T, Stefanidis I, Siamopoulos K, Tzanakis I, Papadogiannakis A, Daphnis E, Iatrou C, Boletis JN, Papagianni A, Goumenos DS

*Clin Kidney J.* 2018 Feb;**11**(1):38-45 *IMPACT FACTOR:* 2.975

**45. Assessment of association between lipoxygenase genes variants in elderly Greek population and type 2 diabetes mellitus**

Tsekmekidou XA, Kotsa KD, Tsetsos FS, Didangelos TP, Georgitsi MA, Roumeliotis AK, Panagoutsos SA, Thodis ED, Theodoridis MT, Papanas NP, Papazoglou DA, Pasadakis PS, Eustratios MS, Paschou PI, Yovos JG  
*Diab Vasc Dis Res. 2018 Jul;15(4):340-343 IMPACT FACTOR: 2.357*

**46. Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension**

Romanidou G, Konstantinidis TG, Koutsogiannis O, Grapsa A, Kantartzi K, Panagoutsos S, Panopoulou M, Tsigalou C

*Med Sci (Basel). 2018 Nov 13;6(4). pii: E102*

**47. Association of matrix gla protein t-138c polymorphism with diabetic nephropathy and vascular calcification**

Roumeliotis, S., Roumeliotis, A., Panagoutsos, S., Theodoridis, M., Kantartzi, K., Tavridou, A., Passadakis, P

*Archives of Hellenic Medicine, (2019) 36 (1), pp. 96-106*

**48. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study**

Bikos A, Loutradis C, Angeloudi E, Karpetas A, Raptis V, Kalaitzidis R, Panagoutsos S, Pasadakis P, Balaskas I, Liakopoulos V, Papagianni A, Sarafidis PA

*J Hypertens. 2019 Feb;37(2):432-442 IMPACT FACTOR: 4.209*

**49. Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension**

Loutradis C, Bikos A, Raptis V, Afkou Z, Tzani G, Pyrgidis N, Panagoutsos S, Pasadakis P, Balaskas E, Zebekakis P, Liakopoulos V, Papagianni A, Parati G, Sarafidis P

*Hypertens Res. 2019 Jul;42(7) IMPACT FACTOR: 3.217*

**50. Immunosuppressive regimens based on Cyclophosphamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy**

Stangou M, Marinaki S, Papachristou E, Kolovou K, Sambani E, Zerbala S, Papadea P, Balafa O, Rapsomanikis KP, Andrikos A, Manolakaki P, Papadopoulou D, Mitsopoulos E, Liakou H, Andronikidi PE, Choulitoudi V, Moustakas G, Galitsiou D, Dafnis E, Stylianos K, Stefanidis I, Golfopoulos S, Panagoutsos S, Tsilivigkou M, Papadogianakis A, Tzanakis I, Sioulis A, Vlachakos D, Grapsa E, Spaia S, Kaperonis N, Paliouras C, Dioudis C, Papoulidou F, Apostolou T, Iatrou C, Boletis I, Goumenos D, Papagianni A

*PLoS One. 2019 Aug 12;14(8):e0217116 IMPACT FACTOR: 2.776*

**51. Use of a temporary shunt to preserve the patency of a hemodialysis graft while performing ipsilateral axillo-femoral bypass**

Argyriou C, Schoretanitis N, Kantartzi K, Panagoutsos S, Souftas VD, Lazarides MK, Georgiadis GS

*J Vasc Access. 2019 Sep;20(5):553-556 IMPACT FACTOR: 1.397*

**52. Reversed connection of cuffed, tunneled, dual-lumen catheters with increased blood flow rate maintains the adequacy of delivered dialysis despite the higher access recirculation**

Kousoula V, Georgianos PI, Mavromatidis K, Syrganis C, Thodis E, Panagoutsos S, Passadakis P

*Int Urol Nephrol. 2019 Oct;51(10):1841-1847 IMPACT FACTOR: 1.596*

**53. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease**

Roumeliotis A, Roumeliotis S, Panagoutsos S, Theodoridis M, Argyriou C, Tavridou A, Georgiadis GS

*Ren Fail. 2019 Nov;41(1):131-138 IMPACT FACTOR: 1.687*

**54. Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients**

Stangou MJ, Marinaki S, Papachristou E, Liapis G, Pateinakis P, Gakiopoulou H, Nikolaidou C, Kolovou K, Lampropoulou IT, Zerbala S, Papadea P, Dounousi E, Balafa O, Pavlaku P, Andrikos A, Balassi E, Manolakaki P, Moustakas G, Galitsiou

D, Mitsopoulos E, Vourlakou C, Choulitoudi V, Andronikidi PE, Stefanidis I, Golfopoulos S, Dafnis E, Stylianos K, Panagoutsos S, Papadogianakis A, Tzanakis I, Sioulis A, Vlahakos D, Grapsa I, Tsilivigkou M, Kaperonis N, Paliouras C, Dioudis C, Spaia S, Apostolou T, Iatrou C, Boletis J, Goumenos D, Papagianni A  
*Histopathology*. 2019 Nov;75(5):660-671 IMPACT FACTOR: 3.294

**55. Association between CUBN gene variants, type 2 diabetes and vitamin D concentrations in an elderly Greek population**

Tsekmekidou X, Tsetsos F, Koufakis T, Karras SN, Georgitsi M, Papanas N, Papazoglou D, Roumeliotis A, Panagoutsos S, Thodis E, Theodoridis M, Pasadakis P, Maltezos E, Paschou P, Kotsa K

*J Steroid Biochem Mol Biol*. 2019 Nov 23:105549 IMPACT FACTOR: 3.785

**56. The Association of dp-ucMGP with Cardiovascular Morbidity and Decreased Renal Function in Diabetic Chronic Kidney Disease.**

Roumeliotis S, Roumeliotis A, Stamou A, Leivaditis K, Kantartzi K, Panagoutsos S, Liakopoulos V.

*Int J Mol Sci*. 2020 Aug 21;21(17):6035. doi: 10.3390/ijms21176035.

**57. Intradialytic Cardiovascular Exercise Training Alters Redox Status, Reduces Inflammation and Improves Physical Performance in Patients with Chronic Kidney Disease.**

Sovatzidis A, Chatzinikolaou A, Fatouros IG, Panagoutsos S, Draganidis D, Nikolaidou E, Avloniti A, Michailidis Y, Mantzouridis I, Batrakoulis A, Pasadakis P, Vargemezis V

*Antioxidants (Basel)*. 2020 Sep 15;9(9):868. doi: 10.3390/antiox9090868.

**58. Fibroblast Growth Factor 23 and  $\alpha$ -Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.**

Manou E, Thodis E, Arsos G, Pasadakis P, Panagoutsos S, Papadopoulou D, Papagianni A.

*Kidney Blood Press Res*. 2020;45(6):900-915. doi: 10.1159/000510351.



**59. ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.**

Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, Kieneker LM, Noordzij M, Pena MJ, Vries H, Arroyo D, Covic A, Crespo M, Goffin E, Islam M, Massy ZA, Montero N, Oliveira JP, Roca Muñoz A, Sanchez JE, Sridharan S, Winzeler R, Gansevoort RT;

*Nephrol Dial Transplant.* 2020 Nov 1;35(11):1973-1983. doi: 10.1093/ndt/gfaa261.

*Erratum in: Nephrol Dial Transplant.* 2021 Feb 24;: PMID: 33151337; PMCID: PMC7665620.

**60. Genetic variation in CARD8, a gene coding for an NLRP3 inflammasome-associated protein, alters the genetic risk for diabetic nephropathy in the context of type 2 diabetes mellitus.**

Tsetsos F, Roumeliotis A, Tsekmekidou X, Alexouda S, Roumeliotis S, Theodoridis M, Thodis E, Panagoutsos S, Papanas N, Papazoglou D, Kotsa K, Yovos JG, Maltezos E, Passadakis P, Paschou P, Georgitsi M.

*Diab Vasc Dis Res.* 2020 Nov-Dec;17(6):1479164120970892. doi:10.1177/1479164120970892.

**61. Red Blood Cell Distribution Width Is Associated with Deterioration of Renal Function and Cardiovascular Morbidity and Mortality in Patients with Diabetic Kidney Disease.**

Roumeliotis S, Stamou A, Roumeliotis A, Theodoridis M, Leivaditis K, Panagoutsos S, Liakopoulos V.

*Life (Basel).* 2020 Nov 22;10(11):301. doi: 10.3390/life10110301.

**62. Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study.**

Roumeliotis S, Liakopoulos V, Roumeliotis A, Stamou A, Panagoutsos S, D'Arrigo G, Tripepi G.

*Int Urol Nephrol.* 2021 Mar 5. doi: 10.1007/s11255-021-02828-4.

**63. Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers.**

Roumeliotis S, Liakopoulos V, Roumeliotis A, Stamou A, Panagoutsos S, D'Arrigo G, Tripepi G.

**Clin Diabetes. 2021 Apr;39(2):188-196. doi: 10.2337/cd20-0067. PMID: 33986571; PMCID: PMC8061536.**

**64. Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.**

Roumeliotis S, Roumeliotis A, Stamou A, Panagoutsos S, Manolopoulos VG, Tsetsos F, Georgitsi M, Liakopoulos V.

*Oxid Med Cell Longev. 2021 May 6;2021:8817502. doi: 10.1155/2021/8817502. PMID: 34040693; PMCID: PMC8121583.*

**65. Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease.**

Roumeliotis S, Georgianos PI, Roumeliotis A, Eleftheriadis T, Stamou A, Manolopoulos VG, Panagoutsos S, Liakopoulos V.

*Life (Basel). 2021 May 29;11(6):504. doi: 10.3390/life11060504. PMID: 34072583; PMCID: PMC8226768.*

**66. Myasthenia gravis genome-wide association study implicates AGRN as a risk locus.**

Topaloudi A, Zagoriti Z, Flint AC, Martinez MB, Yang Z, Tsetsos F, Christou YP, Lagoumintzis G, Yannaki E, Zamba-Papanicolaou E, Tzartos J, Tsekmekidou X, Kotsa K, Maltezos E, Papanas N, Papazoglou D, Passadakis P, Roumeliotis A, Roumeliotis S, Theodoridis M, Thodis E, Panagoutsos S, Yovos J, Stamatoyannopoulos J, Poulas K, Kleopa K, Tzartos S, Georgitsi M, Paschou P.

*J Med Genet. 2021 Aug 16:jmedgenet-2021-107953. doi: 10.1136/jmedgenet-2021-107953. Epub ahead of print. PMID: 34400559.*

**67. Oxidative Stress Genes in Diabetes Mellitus Type 2: Association with Diabetic Kidney Disease.**

Roumeliotis A, Roumeliotis S, Tsetsos F, Georgitsi M, Georgianos PI, Stamou A, Vasilakou A, Kotsa K, Tsekmekidou X, Paschou P, Panagoutsos S, Liakopoulos V.

*Oxid Med Cell Longev.* 2021 Sep 2;2021:2531062. doi: 10.1155/2021/2531062.  
PMID: 34545296; PMCID: PMC8448992.

**68. Variants in clock genes could be associated with lower risk of type 2 diabetes in an elderly Greek population**

Tsekmekidou X.a, Tsetsos F.b, Koufakis T.a, Georgitsi M.c, Papanas N.d, Papazoglou D.d, Roumeliotis A.e, Panagoutsos S.f, Thodis E.f, Theodoridis M.f, Passadakis P.f, Maltezos E.d

*Maturitas Volume 152, Pages 20 – 25 October 2021*

**69. Oxidized LDL Is Associated with eGFR Decline in Proteinuric Diabetic Kidney Disease: A Cohort Study.**

Roumeliotis S, Roumeliotis A, Georgianos PI, Stamou A, Manolopoulos VG, Panagoutsos S, Liakopoulos V.

*Oxid Med Cell Longev.* 2021 Oct 19;2021:2968869.

**70. ERACODA Collaborators. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study.**

Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, Lentini P, Malik S, Reichert LJ, Sever MS, Watschinger B, Jager KJ, Gansevoort RT;.

*Nephrol Dial Transplant.* 2021 Nov 9;36(11):2094-2105

**71. Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study.**

Roumeliotis S, Liakopoulos V, Roumeliotis A, Stamou A, Panagoutsos S, D'Arrigo G, Tripepi G.

*Int Urol Nephrol.* 2021 Dec;53(12):2583-2591.

**72. ERACODA Collaborators. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis.**

Mitra S, Jayanti A, Vart P, Coca A, Gallieni M, Øvrehus MA, Midtvedt K, Abd ElHafeez S, Gandolfini I, Büttner S, Franssen CFM, Hemmeler MH;

*Nephrol Dial Transplant.* 2021 Dec 2;36(12):2308-2320.

**73. Sleep quality in caregivers of patients with end-stage renal disease.**

Arvaniti A, Panagoutsos S, Steiropoulos P, Zoumpouli A, Kantartzi K, Samakouri M. *Psychiatriki*. 2022 Feb 21. doi: 10.22365/jpsych.2022.056.

**74. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA.**

Hemmelder MH, Noordzij M, Vart P, Hilbrands LB, Jager KJ, Abrahams AC, Arroyo D, Battaglia Y, Ekart R, Mallamaci F, Malloney SR, Oliveira J, Rydzewski A, Sridharan S, Vogt L, Duivenvoorden R, Gansevoort RT, Franssen CFM; ERACODA Collaborators.

*Nephrol Dial Transplant*. 2022 May 25;37(6):1140-1151.

**75. Association of obesity with 3-month mortality in kidney failure patients with COVID-19.**

Tantisattamo E, Imhof C, Jager KJ, Hilbrands LB, Guidotti R, Islam M, Katicic D, Konings C, Molenaar FM, Nistor I, Noordzij M, Rodríguez Ferrero ML, Verhoeven MAM, de Vries APJ, Kalantar-Zadeh K, Gansevoort RT, Vart P; ERACODA collaborators.

*Clin Kidney J*. 2022 Mar 21;15(7):1348-1360.

**76. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19.**

Duivenvoorden R, Vart P, Noordzij M, Soares Dos Santos AC Jr, Zulkarnaev AB, Franssen CFM, Kuypers D, Demir E, Rahimzadeh H, Kerschbaum J, Jager KJ, Turkmen K, Hemmelder MH, Schouten M, Rodríguez-Ferrero ML, Crespo M, Gansevoort RT, Hilbrands LB; ERACODA Collaborators

*Transplantation*. 2022 May 1;106(5):1012-1023.

**77. The Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19: an ERACODA analysis.**

Bouwman P, Brandts L, Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Covic A, Islam M, Rabaté C, Jager KJ, Noordzij M, Gansevoort RT, Hemmelder MH; ERACODA collaborators.

*Nephrol Dial Transplant*. 2022 Oct 19;37(11):2264-2274.

**78. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy.**

Vart P, Duivenvoorden R, Adema A, Covic A, Finne P, Braak NH, Laine K, Noordzij M, Schouten M, Jager KJ, Gansevoort RT; ERACODA Collaborators.

*Sci Rep. 2022 Oct 26;12(1):17978.*

**79. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe-lessons for the future.**

Noordzij M, Meijers B, Gansevoort RT, Covic A, Duivenvoorden R, Hilbrands LB, Hemmelder MH, Jager KJ, Mjoen G, Nistor I, Parshina E, Pessolano G, Tuglular S, Vart P, Zanolli L, Franssen CFM; ERACODA collaborators

*Clin Kidney J. 2022 Dec 2;16(4):662-675.*

**80. The Prognostic Role of Automated Office Blood Pressure Measurement in Hypertensive Patients with Chronic Kidney Disease.**

Psounis K, Andreadis E, Oikonomaki T, Roumeliotis S, Margellos V, Thodis E, Passadakis P, Panagoutsos S.

*Healthcare (Basel). 2023 May 9;11(10):1360.*

**81. Decreased Levels of Soluble Developmental Endothelial Locus-1 Are Associated with Thrombotic Microangiopathy in Pregnancy.**

Romanidou G, Konstantinidis TG, Natsi AM, Kantartzi K, Panopoulou M, Kontomanolis E, Tsigalou C, Lambropoulou M, Gavriilaki E, Panagoutsos S, Pasadakis P, Mitroulis I.

*Int J Mol Sci. 2023 Jul 21;24(14):11762.*

**82. Dialysis Patients Respond Adequately to Influenza Vaccination Irrespective of Dialysis Modality and Chronic Inflammation.**

Pleros C, Adamidis K, Kantartzi K, Griveas I, Baltsavia I, Moustakas A, Kalliaropoulos A, Fragedaki E, Petra C, Damianakis N, Mentis A, Drosadaki E, Petrakis I, Passadakis P, Panagopoulos P, Stylianou K, Panagoutsos S.

*J Clin Med. 2023 Sep 26;12(19):6205.*

**83. Recurrence of Idiopathic Membranous Nephropathy in the Kidney Allograft:  
A Systematic Review.**

Panagakis A, Bellos I, Grigorakos K, Panagoutsos S, Passadakis P, Marinaki S.

*Biomedicines. 2024; 12(4):739.*

*Citations*

**Citations: 1454 (SCOPUS), 1746 (GOOGLE SCHOLAR)**

**h-index: 20 (SCOPUS), 23 (GOOGLE SCHOLAR)**